u/Ok_Piglet_6878 · 364d agono track record yet
Novo Nordisk (NVO) - Nov Q3 2025 - Inflexion Point - Doctors Perspective
November Q3 2025 earnings will beat expectations driven by strong international Semaglutide adoption (especially Wegovy in new markets like New Zealand), expanding multi-indication use cases (cardiovascular, MASH, CKD, sleep apnea), and upcoming catalysts including oral Semaglutide FDA decision and Amycretin phase 3 trials. Long-term tailwinds from ubiquitous GLP-1 adoption, healthcare economics, and potential resolution of Trump-era political headwinds make NVO significantly undervalued.
At post $50.38Now $39.05-22.5% since postedas of Oct 23, 4:45 PM ET
1d—
3d-2.9%
1w-6.5%
1m-11.0%
3m+17.7%
6m-19.3%
1y—